This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Harold I. Palevsky, MD; Alfred P. Fishman, MD

JAMA. 1991;265(8):1014-1020.

Abstract
Primary pulmonary hypertension is a clinical syndrome characterized by pulmonary hypertension in the absence of sufficient underlying cardiac, parenchymal pulmonary, or systemic disease to account for it. The population of patients with primary pulmonary hypertension is a heterogeneous one, both clinically and histologically. As the etiologic mechanisms are unknown, therapy is directed toward the consequences of the pulmonary vascular process. Oxygen supplementation, the use of digoxin and diuretics for symptomatic heart failure, and anticoagulation all may have a role in treating primary pulmonary hypertension, although vasodilator therapy has been the main area of investigation. Screening for vasodilator responsiveness, defining a favorable vasodilator effect, predicting long-term effectiveness, and deciding who to treat have all been controversial. New approaches, such as use of high-dose calcium channel-blocking agents and continuous intravenous infusion of prostacyclin (an investigational agent), have recently been proposed. When medical therapies are exhausted, heart-lung or lung transplantation has increasingly become an option for selected patients.

(JAMA. 1991;265:1014-1020)

Author Affiliations
From the Pulmonary and Critical Care Section, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia.

Footnotes
This article is one of a series sponsored by the American Heart Association.

Reprint requests to Pulmonary and Critical Care Section, University of Pennsylvania Medical Center, 975 Maloney Bldg, 3600 Spruce St, Philadelphia, PA 19104-4283 (Dr Palevsky).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase
Janssen et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2001;280:L666-L674.
ABSTRACT | FULL TEXT  

Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
Krasuski et al.
J Am Coll Cardiol 2000;36:2204-2211.
ABSTRACT | FULL TEXT  

Present use of bedside right heart catheterization in patients with cardiac disease
Mueller et al.
J Am Coll Cardiol 1998;32:840-864.
FULL TEXT  

Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension
Raffy et al.
Circulation 1996;93:484-488.
ABSTRACT | FULL TEXT